Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2024

Open Access 01-12-2024 | Bupropion | Research

The effects of bupropion alone and combined with naltrexone on weight loss: a systematic review and meta-regression analysis of randomized controlled trials

Authors: Yang Liu, Fei Han, Zefeng Xia, Ping Sun, Pejman Rohani, Palanisamy Amirthalingam, Mohammad Hassan Sohouli

Published in: Diabetology & Metabolic Syndrome | Issue 1/2024

Login to get access

Abstract

Background

The global prevalence of obesity and overweight is a significant concern in the field of public health. However, addressing and combating these conditions pose considerable challenges. Numerous interventional studies have been conducted to assess the possible impact of bupropion on weight reduction. The primary objective of this study was to conduct a comprehensive investigation into the effects of bupropiona alone and in combination with naltrexone on weight, body mass index (BMI), and waist circumferences (WC).

Methods

A systematic search was conducted in five databases using established keywords. The purpose of this search was to uncover controlled trials that examined the impact of bupropion, either as a standalone intervention or in combination with naltrexone, on weight loss outcomes. The random-effects model analysis was used to provide pooled weighted mean difference and 95% confidence intervals.

Results

Twenty five studies with 22,165 participants’ were included in this article. The pooled findings showed that bupropion administration has an effect on lowering weight (WMD: -3.67 kg, 95% CI: -4.43 to -2.93) and WC (WMD: -2.98 cm, 95% CI -3.78 to -2.19) in compared with control groups. The analysis also showed that the effects of the present intervention on weight and WC during the intervention are > 26 weeks and ≤ 26 weeks compared to the other group, respectively. In addition, changes in weight loss and WC after receiving bupropion together with naltrexone were more compared to bupropion alone.

Conclusions

In conclusion, the addition of combination therapies like bupropion and naltrexone to lifestyle modifications including diet would cause significant weight loss.
Appendix
Available only for authorised users
Literature
1.
go back to reference Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. In: Elsevier; 2022. p. 155217. Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. In: Elsevier; 2022. p. 155217.
2.
go back to reference Lin X, Li H. Obesity: epidemiology, pathophysiology, and therapeutics. Front Endocrinol. 2021;12:706978.CrossRef Lin X, Li H. Obesity: epidemiology, pathophysiology, and therapeutics. Front Endocrinol. 2021;12:706978.CrossRef
3.
go back to reference Nagy É, Cseh V, Barcs I, Ludwig E. The impact of comorbidities and obesity on the severity and outcome of COVID-19 in hospitalized Patients—A retrospective study in a Hungarian hospital. Int J Environ Res Public Health. 2023;20(2):1372.CrossRefPubMedPubMedCentral Nagy É, Cseh V, Barcs I, Ludwig E. The impact of comorbidities and obesity on the severity and outcome of COVID-19 in hospitalized Patients—A retrospective study in a Hungarian hospital. Int J Environ Res Public Health. 2023;20(2):1372.CrossRefPubMedPubMedCentral
4.
go back to reference Lovren F, Teoh H, Verma S. Obesity and atherosclerosis: mechanistic insights. Can J Cardiol. 2015;31(2):177–83.CrossRefPubMed Lovren F, Teoh H, Verma S. Obesity and atherosclerosis: mechanistic insights. Can J Cardiol. 2015;31(2):177–83.CrossRefPubMed
5.
go back to reference Sliwinska A, Kasinska MA, Drzewoski J. MicroRNAs and metabolic disorders–where are we heading? Archives Med Sci. 2017;13(4):885–96.CrossRef Sliwinska A, Kasinska MA, Drzewoski J. MicroRNAs and metabolic disorders–where are we heading? Archives Med Sci. 2017;13(4):885–96.CrossRef
6.
go back to reference Marston OJ, Heisler LK. Targeting the serotonin 2 C receptor for the treatment of obesity and type 2 diabetes. Neuropsychopharmacology: Official Publication Am Coll Neuropsychopharmacol. 2009;34(1):252–3.CrossRef Marston OJ, Heisler LK. Targeting the serotonin 2 C receptor for the treatment of obesity and type 2 diabetes. Neuropsychopharmacology: Official Publication Am Coll Neuropsychopharmacol. 2009;34(1):252–3.CrossRef
7.
go back to reference Fruh SM, Obesity. Risk factors, complications, and strategies for sustainable long-term weight management. J Am Association Nurse Practitioners. 2017;29(S1):S3–14.CrossRef Fruh SM, Obesity. Risk factors, complications, and strategies for sustainable long-term weight management. J Am Association Nurse Practitioners. 2017;29(S1):S3–14.CrossRef
8.
go back to reference Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim care Companion J Clin Psychiatry. 2005;7(3):106.PubMedPubMedCentral Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim care Companion J Clin Psychiatry. 2005;7(3):106.PubMedPubMedCentral
9.
go back to reference Clayton AH, Baker RA, Sheehan JJ, Cain ZJ, Forbes RA, Marler SV, et al. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study. BMC Res Notes. 2014;7:1–11.CrossRef Clayton AH, Baker RA, Sheehan JJ, Cain ZJ, Forbes RA, Marler SV, et al. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study. BMC Res Notes. 2014;7:1–11.CrossRef
10.
go back to reference Blier P, Ward HE, Tremblay P, Laberge L, Hébert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010;167(3):281–8.CrossRefPubMed Blier P, Ward HE, Tremblay P, Laberge L, Hébert C, Bergeron R. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry. 2010;167(3):281–8.CrossRefPubMed
11.
go back to reference Jefferson JW, Rush AJ, Nelson JC, VanMeter SA, Krishen A, Hampton KD, et al. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006;67(6):865–73.CrossRefPubMed Jefferson JW, Rush AJ, Nelson JC, VanMeter SA, Krishen A, Hampton KD, et al. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006;67(6):865–73.CrossRefPubMed
12.
go back to reference Weihs KL, Houser TL, Batey SR, Ascher JA, Bolden-Watson C, Donahue RM, et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry. 2002;51(9):753–61.CrossRefPubMed Weihs KL, Houser TL, Batey SR, Ascher JA, Bolden-Watson C, Donahue RM, et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry. 2002;51(9):753–61.CrossRefPubMed
13.
go back to reference Koshino Y, Bahk W-M, Sakai H, Kobayashi T. The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients. Neuropsychiatr Dis Treat 2013: 1273–80. Koshino Y, Bahk W-M, Sakai H, Kobayashi T. The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients. Neuropsychiatr Dis Treat 2013: 1273–80.
14.
go back to reference Hewett K, Gee MD, Krishen A, Wunderlich H-P, Le Clus A, Evoniuk G, et al. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol. 2010;24(8):1209–16.CrossRefPubMed Hewett K, Gee MD, Krishen A, Wunderlich H-P, Le Clus A, Evoniuk G, et al. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol. 2010;24(8):1209–16.CrossRefPubMed
15.
go back to reference Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Therapeutic Adv Psychopharmacol. 2016;6(2):99–144.CrossRef Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Therapeutic Adv Psychopharmacol. 2016;6(2):99–144.CrossRef
16.
go back to reference Broglio K, Matzo M. CE: Acute pain management for people with opioid use disorder. AJN Am J Nurs. 2018;118(10):30–8.CrossRefPubMed Broglio K, Matzo M. CE: Acute pain management for people with opioid use disorder. AJN Am J Nurs. 2018;118(10):30–8.CrossRefPubMed
17.
go back to reference Yeomans MR, Gray RW. Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehavioral Reviews. 2002;26(6):713–28.CrossRef Yeomans MR, Gray RW. Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehavioral Reviews. 2002;26(6):713–28.CrossRef
18.
go back to reference Greenway FL, Whitehouse M, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, et al. Rational design of a combination medication for the treatment of obesity. Obesity. 2009;17(1):30–9.CrossRefPubMed Greenway FL, Whitehouse M, Guttadauria M, Anderson JW, Atkinson RL, Fujioka K, et al. Rational design of a combination medication for the treatment of obesity. Obesity. 2009;17(1):30–9.CrossRefPubMed
19.
go back to reference Pucci A, Finer N. New medications for treatment of obesity: metabolic and cardiovascular effects. Can J Cardiol. 2015;31(2):142–52.CrossRefPubMed Pucci A, Finer N. New medications for treatment of obesity: metabolic and cardiovascular effects. Can J Cardiol. 2015;31(2):142–52.CrossRefPubMed
20.
go back to reference Greenway FL, Dunayevich E, Tollefson G, Erickson J, Guttadauria M, Fujioka K, et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metabolism. 2009;94(12):4898–906.CrossRef Greenway FL, Dunayevich E, Tollefson G, Erickson J, Guttadauria M, Fujioka K, et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metabolism. 2009;94(12):4898–906.CrossRef
21.
go back to reference Cowley MA, Smart JL, Rubinstein M, Cerdán MG, Diano S, Horvath TL, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature. 2001;411(6836):480–4.CrossRefPubMed Cowley MA, Smart JL, Rubinstein M, Cerdán MG, Diano S, Horvath TL, et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature. 2001;411(6836):480–4.CrossRefPubMed
22.
go back to reference Jain AK, Kaplan RA, Gadde KM, Wadden TA, Allison DB, Brewer ER, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res. 2002;10(10):1049–56.CrossRefPubMed Jain AK, Kaplan RA, Gadde KM, Wadden TA, Allison DB, Brewer ER, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res. 2002;10(10):1049–56.CrossRefPubMed
23.
go back to reference Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Reviews. 2015;4(1):1.CrossRef Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Reviews. 2015;4(1):1.CrossRef
24.
go back to reference Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JA. Assessing risk of bias in a randomized trial. Cochrane Handb Syst Reviews Interventions 2019: 205–28. Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JA. Assessing risk of bias in a randomized trial. Cochrane Handb Syst Reviews Interventions 2019: 205–28.
25.
go back to reference Schwingshackl L, Knüppel S, Schwedhelm C, Hoffmann G, Missbach B, Stelmach-Mardas M, et al. Perspective: NutriGrade: a Scoring System to assess and judge the Meta-evidence of Randomized controlled trials and Cohort studies in Nutrition Research. Adv Nutr. 2016;7(6):994–1004.CrossRefPubMedPubMedCentral Schwingshackl L, Knüppel S, Schwedhelm C, Hoffmann G, Missbach B, Stelmach-Mardas M, et al. Perspective: NutriGrade: a Scoring System to assess and judge the Meta-evidence of Randomized controlled trials and Cohort studies in Nutrition Research. Adv Nutr. 2016;7(6):994–1004.CrossRefPubMedPubMedCentral
26.
go back to reference Higgins J. Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbook. org 2011. Higgins J. Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbook. org 2011.
27.
30.
go back to reference Powell-Wiley TM, Poirier P, Burke LE, Després J-P, Gordon-Larsen P, Lavie CJ, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984–1010.CrossRefPubMedPubMedCentral Powell-Wiley TM, Poirier P, Burke LE, Després J-P, Gordon-Larsen P, Lavie CJ, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984–1010.CrossRefPubMedPubMedCentral
31.
go back to reference Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR‐II). Obesity. 2013;21(5):935–43.CrossRefPubMed Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR‐II). Obesity. 2013;21(5):935–43.CrossRefPubMed
32.
go back to reference Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595–605.CrossRefPubMed Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595–605.CrossRefPubMed
33.
go back to reference Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, et al. Effect of naltrexone-bupropion on major adverse Cardiovascular events in overweight and obese patients with Cardiovascular Risk factors: a Randomized Clinical Trial. JAMA. 2016;315(10):990–1004.CrossRefPubMed Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, et al. Effect of naltrexone-bupropion on major adverse Cardiovascular events in overweight and obese patients with Cardiovascular Risk factors: a Randomized Clinical Trial. JAMA. 2016;315(10):990–1004.CrossRefPubMed
34.
go back to reference le Roux CW, Fils-Aimé N, Camacho F, Gould E, Barakat M. The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy. Eclinicalmedicine. 2022;49:101436.CrossRefPubMedPubMedCentral le Roux CW, Fils-Aimé N, Camacho F, Gould E, Barakat M. The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy. Eclinicalmedicine. 2022;49:101436.CrossRefPubMedPubMedCentral
35.
go back to reference Dulloo AG, Montani JP. Pathways from dieting to weight regain, to obesity and to the metabolic syndrome: an overview. Obes Rev. 2015;16:1–6.CrossRefPubMed Dulloo AG, Montani JP. Pathways from dieting to weight regain, to obesity and to the metabolic syndrome: an overview. Obes Rev. 2015;16:1–6.CrossRefPubMed
36.
go back to reference Anderson J, Konz EC, Frederich RC, Wood CL. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr. 2001;74:579–84.CrossRefPubMed Anderson J, Konz EC, Frederich RC, Wood CL. Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr. 2001;74:579–84.CrossRefPubMed
37.
go back to reference Thomas J, Bond D, Phelan S, Hill J, Wing R. 10-year weight loss maintenance in the national weight control registry (NWCR). Am J Prev Med 2013. Thomas J, Bond D, Phelan S, Hill J, Wing R. 10-year weight loss maintenance in the national weight control registry (NWCR). Am J Prev Med 2013.
38.
go back to reference Billes SK, Cowley MA. Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice. Neuropsychopharmacology. 2007;32(4):822–34.CrossRefPubMed Billes SK, Cowley MA. Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice. Neuropsychopharmacology. 2007;32(4):822–34.CrossRefPubMed
39.
go back to reference Wright F, Rodgers RJ. Acute behavioural effects of bupropion and naltrexone, alone and in combination, in non-deprived male rats presented with palatable mash. Psychopharmacology. 2013;228:291–307.CrossRefPubMed Wright F, Rodgers RJ. Acute behavioural effects of bupropion and naltrexone, alone and in combination, in non-deprived male rats presented with palatable mash. Psychopharmacology. 2013;228:291–307.CrossRefPubMed
Metadata
Title
The effects of bupropion alone and combined with naltrexone on weight loss: a systematic review and meta-regression analysis of randomized controlled trials
Authors
Yang Liu
Fei Han
Zefeng Xia
Ping Sun
Pejman Rohani
Palanisamy Amirthalingam
Mohammad Hassan Sohouli
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2024
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-024-01319-7

Other articles of this Issue 1/2024

Diabetology & Metabolic Syndrome 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.